Core Insights - Vivoryon Therapeutics N.V. reported its Q1 2025 financial results and operational progress, focusing on the development of varoglutamstat for kidney diseases, particularly diabetic kidney disease (DKD) [2][3] Financial Performance - Revenues for Q1 2025 were zero, consistent with Q1 2024 [14] - Research and development expenses decreased by EUR 6.2 million to EUR 1.2 million in Q1 2025 from EUR 7.4 million in Q1 2024, primarily due to lower third-party expenses [14][16] - General and administrative expenses were EUR 1.3 million in Q1 2025, down from EUR 2.1 million in Q1 2024 [16] - Net loss for Q1 2025 was EUR 2.5 million, compared to EUR 9.3 million in Q1 2024 [17] - Cash and cash equivalents as of March 31, 2025, were EUR 7.0 million, down from EUR 9.4 million as of December 31, 2024 [17] Clinical Development - The company is advancing varoglutamstat in kidney disease, with a planned Phase 2b study in DKD as a priority for 2025 [9] - A meta-analysis confirmed that varoglutamstat at 600mg twice daily significantly improved eGFR kidney function, with effects sustained until week 96 [7] - Preclinical data showed a synergistic effect of varoglutamstat in combination with SGLT-2 inhibitors, indicating potential for enhanced treatment regimens [5][6] Intellectual Property - A new composition of matter patent for varoglutamstat was granted in the U.S., providing exclusivity through 2044, with potential extensions [10] - The company is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease [10] Corporate Developments - Vivoryon entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors for up to EUR 15 million in ordinary shares over the next 36 months, enhancing financial flexibility [12] - Julia Neugebauer was appointed as Chief Operating Officer, effective May 1, 2025, to oversee investor relations and corporate functions [13] Pipeline Updates - The company has nominated a new candidate, VY2149, a next-generation QPCT/L inhibitor, expected to enter late-stage preclinical development [11]

Core Viewpoint - Vivoryon Therapeutics N.V. is set to report its Q1 2025 financial results and operational progress on June 17, 2025, focusing on its development of small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [1][3]. Group 1: Financial Results Announcement - The company will publish its first quarter financial results for the period ended March 31, 2025, on June 17, 2025 [1]. - A corporate update will accompany the financial results announcement [1]. Group 2: Conference Call Details - A conference call will be held on June 17, 2025, at 3:00 pm CEST / 9:00 am EDT, available via phone and webcast [2]. - Participants are encouraged to pre-register for the call to receive dedicated dial-in details and should join 15 minutes early to avoid delays [2]. Group 3: Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3]. - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for diabetic kidney disease [3].

Core Insights - Vivoryon Therapeutics N.V. presented meta-analysis data for its lead drug varoglutamstat at the 62nd ERA Congress, highlighting significant improvements in kidney function [1][2][3] Group 1: Drug Development and Efficacy - Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with notable anti-inflammatory and anti-fibrotic effects [3] - The Phase 2 studies, VIVIAD and VIVA-MIND, demonstrated statistically significant and clinically meaningful improvements in estimated glomerular filtration rate (eGFR) in elderly patients, with effects sustained from week 24 to week 96 [3] - The meta-analysis indicated a larger effect size in participants with diabetes compared to those without [3] Group 2: Future Plans - The next step involves a dedicated Phase 2b trial focusing on patients with diabetic kidney disease, aiming to assess efficacy on eGFR and gather data on proteinuria and other kidney-specific markers [4] Group 3: Presentation Details - The presentation took place on June 6, 2025, at 8:15 am CEST in Vienna, Austria, led by Frank Weber, CEO of Vivoryon Therapeutics [5]

Core Viewpoint - Vivoryon Therapeutics N.V. has been granted a new U.S. patent for its lead drug varoglutamstat, enhancing its intellectual property portfolio and supporting its development strategy in kidney disease [2][3][7]. Group 1: Patent Details - The newly granted U.S. composition of matter patent (US 12,312,335) covers the only polymorph of the salt form used in varoglutamstat, with a patent term extending through 2044 and potential extension to 2049 under the Hatch-Waxman Act [3][4]. - The patent was granted after an accelerated examination process, indicating the efficiency and effectiveness of the company's patent application strategy [2][3]. Group 2: Strategic Focus - Vivoryon is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease, including medical use and dosing regimens, both as monotherapy and in combination with SGLT-2 inhibitors [4][5]. - The company has filed multiple patents in the past months, reflecting its commitment to strengthening its intellectual property in the field of kidney diseases [4][5]. Group 3: Broader Patent Portfolio - Vivoryon has developed a robust patent portfolio for QPCT/L inhibitors, encompassing over 20 patent families and more than 400 patent applications and issued patents across major markets [6]. - The majority of the patents focus on composition of matter for QPCT/L inhibitors, with recent applications emphasizing the company's focus on kidney diseases and the synergistic effects observed in preclinical research [5][6].

Core Viewpoint - Vivoryon Therapeutics N.V. has announced its 2025 Annual General Meeting scheduled for June 24, 2025, focusing on its clinical stage biotechnology initiatives aimed at developing small molecule medicines for various severe diseases [1]. Company Overview - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company dedicated to the discovery and development of innovative small molecule-based medicines [2]. - The company aims to improve the lives of patients suffering from severe diseases by leveraging its expertise in post-translational modifications to develop medicines that modulate the activity and stability of pathologically altered proteins [2]. - Vivoryon has established a pipeline of orally available small molecule inhibitors targeting conditions such as Alzheimer's disease, inflammatory and fibrotic disorders, including kidney issues, and cancer [2].

Core Insights - Vivoryon Therapeutics N.V. has reported a transformative year in 2024, successfully shifting its focus towards kidney disease with a viable commercial strategy and strong intellectual property (IP) [3][4] - The company has designed a Phase 2b study for varoglutamstat in diabetic kidney disease (DKD), leveraging statistical evidence from previous studies to maximize the probability of success [4][12] - Financial results indicate a net loss of EUR 20.6 million for 2024, a decrease from EUR 28.3 million in 2023, with cash and cash equivalents of EUR 9.4 million as of December 31, 2024 [30][33] Financial Performance - No revenues were generated in 2024 [27] - Research and development expenses decreased by EUR 3.6 million to EUR 14.1 million, primarily due to lower third-party expenses [28] - General and administrative expenses were EUR 6.9 million, down from EUR 8.6 million in 2023, attributed to lower personnel and legal costs [29] - Cash flows used in operating activities were EUR 19.2 million, compared to EUR 21.5 million in 2023 [31] Strategic Developments - The company has entered into a Standby Equity Purchase Agreement (SEPA) of up to EUR 15 million with Yorkville Advisors, providing financial flexibility for advancing its kidney disease strategy [4][26] - A new varoglutamstat composition of matter patent has been allowed in the U.S., strengthening the company's IP portfolio [4][23] - The management team has been expanded with the addition of Julia Neugebauer as Chief Operating Officer, effective May 1, 2025 [4][26] Clinical Pipeline and Research - Varoglutamstat has shown statistically significant improvement in kidney function (eGFR) in Phase 2 studies, with a notable effect size in diabetic patients [4][12] - The company plans to conduct a Phase 2b clinical study in DKD, targeting approximately 90 subjects with advanced stages of the disease [18] - Pre-clinical data indicates a synergistic effect of varoglutamstat in combination with SGLT2 inhibitors, supporting its potential in treating kidney diseases [21] Future Outlook - Vivoryon expects its cash and cash equivalents to fund operations into January 2026, excluding funds from the SEPA [33][34] - The company aims to confirm previous compelling data from its Phase 2 studies and advance varoglutamstat in kidney disease [18][34] - The identification of a next-generation QPCT/L inhibitor, VY2149, is underway, with plans for late-stage pre-clinical development [20][25]

Core Viewpoint - Vivoryon Therapeutics N.V. has signed a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global, LP for up to EUR 15 million to support its clinical development efforts, particularly for its Phase 2b study in diabetic kidney disease [2][3][4] Financing Agreement Details - The SEPA allows Yorkville to purchase up to EUR 15 million of ordinary shares over 36 months, with Vivoryon having the right to sell shares in individual tranches [3] - Each tranche can include shares equal to 100% of the average daily trading volume over the previous five trading days, with a maximum of 389,359 shares per tranche, subject to mutual consent for increases [4] - Shares will be issued at a 5% discount to the prevailing market price, and an additional 167,028 shares will be issued to Yorkville as a commitment fee [4] Use of Funds - Funds raised through the SEPA will be utilized for ongoing business operations, preparation for the Phase 2b study of varoglutamstat, and advancing preclinical studies of the new candidate VY2149 [5] Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing small molecule medicines targeting pathologically altered proteins, with a pipeline that includes treatments for Alzheimer's disease, kidney disorders, and cancer [6]